前列腺癌PSMA PET/CT显像的应用现状与思考  

Current status and thoughts of PSMA PET/CT imaging application for prostate cancer

作　　者：段小艺[1] DUAN Xiaoyi(PET‒CT Center,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)

机构地区：[1]西安交通大学第一附属医院PET/CT室,陕西西安710061

出　　处：《西安交通大学学报（医学版）》2022年第2期163-167,共5页Journal of Xi’an Jiaotong University（Medical Sciences）

基　　金：西安交通大学第一附属医院临床研究项目(No.XJTU1AF-CRF-2020-008);西安交通大学第一附属医院新医疗新技术项目(No.XJYFY-2019J1)。

摘　　要：近年来,靶向前列腺特异性膜抗原(PSMA)PET/CT成像在前列腺癌诊疗中应用逐渐增多。PSMA PET/CT对前列腺癌原发及转移灶检测灵敏度高、特异性强、诊断效能好,适用于前列腺癌分期、再分期、早期生化复发的检测,尤其对于隐匿性淋巴结和骨转移检测,较常规影像学方法更准确、更全面。在前列腺癌肿瘤定位、放疗生物靶区勾画、疗效评价、预后预测方面,PSMA PET/CT亦显示出较好的应用前景,可能成为未来的临床适应证。假阳性、假阴性问题依然是困扰成像结果判断的重要因素,随着临床经验的不断积累及临床研究的不断深入,报告的准确性也逐渐提高。In recent years,PET/CT imaging targeting prostate specific membrane antigen(PSMA)has been increasingly used in the diagnosis and treatment of prostate cancer.PSMA PET/CT has high sensitivity,strong specificity and good diagnostic efficiency for primary and metastatic lesions in prostate cancer.It is suitable for staging,restaging and detection of early biochemical recurrence.It is more accurate and comprehensive than conventional imaging methods for detection of occult lymph node and bone metastasis.Moreover,PSMA PET/CT shows good application prospects in tumor localization,radiotherapy biological target contour,efficacy evaluation,and prognosis prediction of prostate cancer,and may become a clinical indication in the future.False positive and false negative are important problems affecting the judgment of imaging.With the continuous accumulation of clinical experience and constant in-depth clinical research,the reporting accuracy will continue to improve.

关 键 词：前列腺癌 前列腺特异性膜抗原 正电子发射断层显像术 X线体层摄影术 

分 类 号：R737.25[医药卫生—肿瘤]